

Bruce Chabner, MD has extensive experience in the field of cancer drug discovery and development. During his career at the National Cancer Institute (NCI), he served as a Senior Investigator in the Laboratory of Chemical Pharmacology, Chief of the Clinical Pharmacology Branch, Director of the Clinical Oncology Program and Director of the Division of Cancer Treatment.

At the NCI he maintained an active laboratory program in cancer pharmacology and led the development of *Taxol*. His research contributed significantly to the development of high dose chemotherapy regimens and to standard therapies for lymphoma.

Dr. Chabner is a senior editor for the *Oncologist* and serves on the executive advisory boards for some of the industry's leading innovators in drug development. In 2006, he received a presidential appointment to the National Cancer Advisory Board at the NCI.